GWA
VRTX icon

Guidant Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Guidant Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7
Closed -$1K – 294
2018
Q1 		$1K Buy
+7
New +$1.14K ﹤0.01% 205

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Guidant Wealth Advisors's VRTX Position: Q2 2018 in Review

Guidant Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 7 shares — an estimated $1K sold.

Guidant Wealth Advisors first reported a position in VRTX in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 689 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

  • Guidant Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Guidant Wealth Advisors sold 7 Vertex Pharmaceuticals shares in Q2 2018, an estimated $1K.
  • Guidant Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Guidant Wealth Advisors's Vertex Pharmaceuticals position peaked at $1K in Q1 2018.
  • 689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Guidant Wealth Advisors's 13F filing for Q2 2018, filed 11 Jul 2018.